ProKidney (NASDAQ:PROK – Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $0.10 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.
ProKidney (NASDAQ:PROK – Get Free Report) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.00 million. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
ProKidney Stock Down 1.8%
NASDAQ:PROK traded down $0.04 during trading hours on Monday, hitting $1.90. 323,798 shares of the company’s stock traded hands, compared to its average volume of 891,202. The firm has a market cap of $572.13 million, a P/E ratio of -3.66 and a beta of 1.70. ProKidney has a 52 week low of $0.54 and a 52 week high of $7.13. The business’s fifty day simple moving average is $2.04 and its two-hundred day simple moving average is $2.27.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on ProKidney
Institutional Investors Weigh In On ProKidney
Several hedge funds have recently added to or reduced their stakes in PROK. AQR Capital Management LLC lifted its stake in shares of ProKidney by 106.4% in the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after acquiring an additional 27,098 shares during the last quarter. JPMorgan Chase & Co. raised its position in ProKidney by 3,024.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company’s stock valued at $988,000 after purchasing an additional 1,615,243 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of ProKidney during the 2nd quarter worth approximately $274,000. Jane Street Group LLC purchased a new position in shares of ProKidney during the 2nd quarter worth approximately $350,000. Finally, Bank of America Corp DE grew its holdings in shares of ProKidney by 12.4% during the 2nd quarter. Bank of America Corp DE now owns 846,154 shares of the company’s stock worth $501,000 after acquiring an additional 93,322 shares during the period. Institutional investors own 51.59% of the company’s stock.
About ProKidney
ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.
ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.
Read More
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
